Entamoeba histolytica is a protozoan parasite that can cause amebiasis. Some infected people have no symptoms; others develop intestinal disease. The species name matters because several similar-looking intestinal amoebae are not considered causes of disease.
On this page
Why species identification matters
Microscopy may have difficulty distinguishing E. histolytica from look-alike organisms such as E. dispar. Species-specific molecular methods can help resolve that distinction. Entamoeba coli is another amoeba entirely; it is neither E. histolytica nor the E. coli bacterium. [1]
How GI-MAP relates to amebiasis testing
GI-MAP includes an E. histolytica DNA target. A detected result provides information about the submitted stool, but it does not reveal whether the parasite has invaded tissue or spread beyond the intestine. Ask a clinician whether the result needs confirmation using an appropriate clinical laboratory method. [2]
Symptoms and exposure guide follow-up
Amebiasis can cause diarrhea and abdominal pain; invasive intestinal disease may involve blood in stool. Travel, residence or exposures where sanitation is inadequate can be relevant. Severe abdominal pain, bloody diarrhea or fever needs prompt medical assessment. E. histolytica can also cause disease outside the intestine, such as liver abscess, which cannot be diagnosed or excluded by a GI-MAP stool number. [1]
What a negative finding leaves unanswered
A negative result is limited to the tested sample and target. Ongoing symptoms may require additional stool samples, different testing or evaluation for other conditions. It does not establish that all parasites are absent. Do not use an undetected stool target to dismiss symptoms suggesting disease elsewhere in the body.
Common questions
Is E. histolytica always harmless if I feel well?
No. Lack of symptoms does not settle the clinical significance. A clinician should review a detected result and decide on confirmation and management.
Can I choose a parasite cleanse from this result?
No. Confirmed amebiasis requires a clinician-directed plan. Products marketed as cleanses are not a substitute for identifying the infection and the appropriate care.
Sources and review
Sources checked October 7, 2026. Manufacturer material describes the test; clinical guidance and research support the interpretation limits.
- CDC DPDx: Amebiasis
- Diagnostic Solutions Laboratory: GI-MAP interpretive guide (manufacturer specifications)
Medical review of this article is pending. For a correction or source question, contact GI MAP Test.